Shows
Markintel Pulse InsightsThe 2026 AI Playbook: Workflow Control, Aidoc's $150M Raise & GE's Margin ResetThe moat for imaging AI has officially shifted from isolated model performance to capitalized platform scale, workflow ownership, and operating leverage. This week on Marketstrat Pulse Insights for May 1, 2026, we break down what this means for the future of healthcare technology.We explore Aidoc's massive $150 million Series E funding round, which sets a new scale-capital bar for enterprise AI operating systems. We also dive into GE HealthCare's transition from a product stack to an operating stack with its $14.6 billion Advanced Imaging Solutions segment, alongside the harsh reality of margin pressures from tariffs, memory chips, and freight.
2026-05-0404 minMarkintel Pulse InsightsCoverage Speed is the New Moat: RAPID, Covera/Medmo & MRI ThroughputThe market's center of gravity is moving from basic algorithm adoption to reimbursable, evidence-governed workflow infrastructure. This week on Marketstrat Pulse Insights for April 24, 2026, we break down the new CMS and FDA RAPID pathway, which could radically reduce Medicare coverage timing for eligible Breakthrough Devices to roughly two months post-authorization.We also cover the combination of Covera Health and Medmo, a massive move that shifts imaging control upstream into order capture, patient routing, and quality analytics. Plus, we look at tangible AI capacity proof from Spire's 21-site AI-MRI rollout, Philips’ Rembra CT platform clearance, and a new st...
2026-05-0304 minMarkintel Pulse InsightsOwned Workflow Gets Paid: Reimbursable AI, Sectra M&A & ARRS Reality ChecksThe era of the standalone AI algorithm is giving way to a new commercial reality: owned workflow surfaces are starting to get paid. This week on Marketstrat Pulse Insights for April 17, 2026, we break down how opportunistic AI is finally monetizing, and why platform control is tightening across the imaging industry.We explore Bunkerhill’s breakthrough in securing both FDA clearance and a CMS OPPS payment pathway for contrast-chest-CT calcium AI, proving that attachable AI can drive revenue without needing new scanner time. We also dive into massive platform consolidation moves, including Sectra closing its acquisition of Oxipit to...
2026-04-2304 minMarkintel Pulse InsightsPlatform Control, Breast AI Labor Proof & Cyber Reality ChecksEpisode Description / Show Notes:The era of standalone medical AI is fading as tech giants move to own the digital infrastructure. This week on Marketstrat Pulse Insights for March 20, 2026, we break down GE HealthCare's $2.3 billion acquisition of Intelerad and what it means for enterprise imaging control.We also dive into new prospective evidence from Nature Medicine showing breast screening AI can cut radiologist workload by 63.6% —but why higher recall rates mean the economic case is still complex. Finally, we cover the real-world fallout of the Stryker cyberattack on scheduled surgeries , and the alarming JAMA fi...
2026-03-2604 minMarkintel Pulse InsightsHIMSS26 & The AI Control Surface: Workflow, Helium Risk, and MIS AutomationEpisode Description / Show Notes: The era of the standalone AI algorithm is officially over. This week on Marketstrat Pulse Insights for March 13, 2026, we break down the massive shift toward enterprise imaging orchestration dominating the floor at HIMSS26. Hospitals are no longer buying abstract AI; they are buying relief from workflow bottlenecks.We explore how vendors like GE HealthCare and Brainomix are scaling AI as true hospital infrastructure , while new regulatory tracking, reimbursement friction, and physical supply chain shocks change the rules of the game.More on this Pulse Research Note and view our data charts: https://marketstrat.com/articles-news...
2026-03-1704 minMarkintel Pulse InsightsMedical Imaging AI Grows Up: Consolidation, ECR 2026 & Reimbursement Reality ChecksEpisode Summary:The era of the standalone medical AI algorithm is officially over. This week on Marketstrat Pulse Insights, AI host Marcus breaks down the rapid shift toward bundled, heavy-duty AI infrastructure in hospitals. From massive market consolidation to the latest vendor strategies at ECR 2026, we explore why the winners in healthcare AI won't just have the flashiest code—they’ll have the best hospital integration and the strongest reimbursement strategies.In this episode, we cover:The "AI Operating System" Race: Why heavyweights like RadNet (Gleamer) and Sectra (Oxipit) are acquiring platforms to c...
2026-03-0904 minMarkintel Pulse InsightsRadNet’s $250M Gleamer Deal, GE’s "Virtual Capacity" & AI as InfrastructureIn this week’s Markintel Pulse (Week of Feb 27, 2026), we explore a massive shift in healthcare technology: AI is officially moving from a "shiny point-solution" to fundamental hospital infrastructure.Key Signals Covered:The Deal of the Year: RadNet acquires French AI firm Gleamer for $250M, plugging it into DeepHealth to build the largest radiology AI operating system on the planet.Hidden Capacity: GE HealthCare signs a 10-year Care Alliance with UCSF Health. We run the math on how a 5% uptime boost and 3% cycle-time increase creates the equivalent of a "free" MRI scanner....
2026-03-0305 minMarkintel Pulse InsightsTariff Reset (15% Cost) & The Robot Fleet War: Medtronic vs. Intuitive vs. J&JEpisode Description:In this week’s Markintel Pulse (Week of Feb 20, 2026), we break down the shift from "Executive Volatility" to "Legislative Uncertainty."Key Signals Covered:The Tariff Reset: Supreme Court strikes down IEEPA, but the new 15% Section 122 surcharge creates a confirmed cost headwind while Congress debates the permanent fix.The Robot War: Medtronic lands its first U.S. commercial Hugo case, while Banner Health adds 49 robots. We analyze how this impacts Intuitive Surgical and Johnson & Johnson's platform strategies.Imaging Speed: GE HealthCare clears SIGNA Sprint/Bolt—shifting the sale...
2026-02-2404 minMarkintel Pulse InsightsThe Reimbursement Cliff: Imaging AI’s $575 Risk, Median’s Clearance & Tempus DistributionEpisode Description:In this week’s Markintel Pulse (Week of Feb 13, 2026), we analyze the massive financial spread defining Imaging AI economics.Key Signals Covered:The Reimbursement Cliff: CMS keeps AI CT codes in APC 1508 (~$650), but claims data suggests a repricing risk to ~$75. We break down the $57.5M revenue swing.Median Technologies (eyonis): FDA clearance for Lung Cancer Screening AI + a strategic distribution deal with Tempus Pixel.Distribution Wars: Why "Commercial Rails" (Tempus, RadNet, HealthMark) are replacing direct sales models.Platform Economics: Pro Medicus results reinforce why "In...
2026-02-1704 minMarkintel Pulse InsightsROI Telemetry is the New Moat: NGS Non-Coverage, RapidAI & MedtronicEpisode Description:In this week’s Markintel Pulse briefing (Week of Feb 6, 2026), we break down why "Accuracy" is no longer the winning sales pitch for Imaging AI.Key Signals Covered:The Reimbursement Warning: NGS releases a draft LCD proposing non-coverage for brain MRI AI quantification. We explain why FDA clearance no longer guarantees revenue.The New Moat: RapidAI releases operational telemetry (staff-hours saved, incremental scans) at ISC. This is the new template for procurement-grade ROI.Vertical Integration: Medtronic moves to acquire CathWorks (~$585M), signaling that cardiology AI is being absorbed into th...
2026-02-0904 minMarkintel Pulse InsightsImaging AI Becomes Infrastructure: The MASAI Outcomes, New CPT Codes & The "Quant" EraEpisode Description:In this week’s Markintel Pulse briefing (Week of Jan 30, 2026), we break down the shift from "AI Pilots" to "Critical Infrastructure."Key Signals Covered:The "Outcomes" Breakthrough: The MASAI trial reports a ~12% reduction in interval cancer rates with AI-supported mammography. We discuss why this "outcome-grade" evidence is the new bar for tenders.Reimbursement Wins: CPT 75577 (Category I) is effective for Coronary Plaque AI. We analyze why billing pathways are driving adoption faster than clinical utility alone.The Rise of "Quant": New clearances from Spectrum Dynamics (SPECT/CT noise reduction) and MIM So...
2026-01-3104 minMarkintel Pulse InsightsRadiology AI: The Shift from Apps to Platforms (Aidoc, BMS + Microsoft, & The New ROI)In this week’s Markintel Pulse briefing (Week of Jan 23, 2026), we analyze the structural shift in Radiology AI from single-point "apps" to enterprise-grade platforms.Key Signals Covered:The Platform Win: Aidoc secures FDA clearance for its "Comprehensive Abdomen CT Triage," bundling 14 clinical findings into a single workflow. We discuss why "Integration Fatigue" is driving the market toward bundles.Pharma Enters the Chat: Bristol Myers Squibb and Microsoft launch the "Precision Imaging Network" for lung cancer. This signals that imaging data is evolving into a pharma-grade biomarker asset.The Payer Wa...
2026-01-2904 minMarkintel Pulse InsightsMRI Automation, The $14.5B Stroke Deal, and Google's Open Models (Jan 16, 2026)This Week on the Pulse:MRI Automation: Why Vista AI's $29.5M raise signals a shift from "detection" to "capacity."Strategic M&A: Inside Boston Scientific’s $14.5B acquisition of Penumbra.Tech Layer: Google releases MedGemma 1.5—what open models mean for your competitive moat.About This Episode:This briefing is based on the "Markintel Pulse Insights" published on January 16, 2026.Read the full data set: https://marketstrat.com/articles-news/markintel-pulse-insights-mri-automation-becomes-the-capacity-lever-jan-16-2026/#Disclaimer: This podcast is produced by Marketstrat Inc. The voice narration is AI-generated ("Marcus" / "Zara") to deliver our late...
2026-01-2803 min